These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 35006452)

  • 21. Molecular mechanism of SAHA on regulation of autophagic cell death in tamoxifen-resistant MCF-7 breast cancer cells.
    Lee YJ; Won AJ; Lee J; Jung JH; Yoon S; Lee BM; Kim HS
    Int J Med Sci; 2012; 9(10):881-93. PubMed ID: 23155362
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HOXB5 Confers Tamoxifen Resistance in Breast Cancer Cells and Promotes Tumor Aggression and Progression.
    Kim CY; Kim YC; Oh JH; Kim MH
    Anticancer Res; 2021 Jul; 41(7):3409-3417. PubMed ID: 34230136
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Matrix Metalloproteinase-1 (MMP1) Upregulation through Promoter Hypomethylation Enhances Tamoxifen Resistance in Breast Cancer.
    Kim HW; Park JE; Baek M; Kim H; Ji HW; Yun SH; Jeong D; Ham J; Park S; Lu X; Kang HS; Kim SJ
    Cancers (Basel); 2022 Feb; 14(5):. PubMed ID: 35267540
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Overexpression of CD44 accompanies acquired tamoxifen resistance in MCF7 cells and augments their sensitivity to the stromal factors, heregulin and hyaluronan.
    Hiscox S; Baruha B; Smith C; Bellerby R; Goddard L; Jordan N; Poghosyan Z; Nicholson RI; Barrett-Lee P; Gee J
    BMC Cancer; 2012 Oct; 12():458. PubMed ID: 23039365
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acquired Tamoxifen Resistance in MCF-7 Breast Cancer Cells Requires Hyperactivation of eIF4F-Mediated Translation.
    Fagan DH; Fettig LM; Avdulov S; Beckwith H; Peterson MS; Ho YY; Wang F; Polunovsky VA; Yee D
    Horm Cancer; 2017 Aug; 8(4):219-229. PubMed ID: 28577281
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Src Is a Potential Therapeutic Target in Endocrine-Resistant Breast Cancer Exhibiting Low Estrogen Receptor-Mediated Transactivation.
    Guest SK; Ribas R; Pancholi S; Nikitorowicz-Buniak J; Simigdala N; Dowsett M; Johnston SR; Martin LA
    PLoS One; 2016; 11(6):e0157397. PubMed ID: 27308830
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Post-transcriptional regulation of ERBB2 by miR26a/b and HuR confers resistance to tamoxifen in estrogen receptor-positive breast cancer cells.
    Tan S; Ding K; Chong QY; Zhao J; Liu Y; Shao Y; Zhang Y; Yu Q; Xiong Z; Zhang W; Zhang M; Li G; Li X; Kong X; Ahmad A; Wu Z; Wu Q; Zhao X; Lobie PE; Zhu T
    J Biol Chem; 2017 Aug; 292(33):13551-13564. PubMed ID: 28637868
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting of the adaptor protein Tab2 as a novel approach to revert tamoxifen resistance in breast cancer cells.
    Cutrupi S; Reineri S; Panetto A; Grosso E; Caizzi L; Ricci L; Friard O; Agati S; Scatolini M; Chiorino G; Lykkesfeldt AE; De Bortoli M
    Oncogene; 2012 Oct; 31(40):4353-61. PubMed ID: 22249258
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibiting PAD2 enhances the anti-tumor effect of docetaxel in tamoxifen-resistant breast cancer cells.
    Li F; Miao L; Xue T; Qin H; Mondal S; Thompson PR; Coonrod SA; Liu X; Zhang X
    J Exp Clin Cancer Res; 2019 Oct; 38(1):414. PubMed ID: 31601253
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer.
    Ward A; Balwierz A; Zhang JD; Küblbeck M; Pawitan Y; Hielscher T; Wiemann S; Sahin Ö
    Oncogene; 2013 Feb; 32(9):1173-82. PubMed ID: 22508479
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Competing endogenous RNA networks of CYP4Z1 and pseudogene CYP4Z2P confer tamoxifen resistance in breast cancer.
    Zheng L; Li X; Meng X; Chou J; Hu J; Zhang F; Zhang Z; Xing Y; Liu Y; Xi T
    Mol Cell Endocrinol; 2016 May; 427():133-42. PubMed ID: 26980484
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gene expression profiling identifies FYN as an important molecule in tamoxifen resistance and a predictor of early recurrence in patients treated with endocrine therapy.
    Elias D; Vever H; Lænkholm AV; Gjerstorff MF; Yde CW; Lykkesfeldt AE; Ditzel HJ
    Oncogene; 2015 Apr; 34(15):1919-27. PubMed ID: 24882577
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Urothelial carcinoma-associated 1 enhances tamoxifen resistance in breast cancer cells through competitively inhibiting miR-18a].
    Li XN; Liu AH; Tang X; Ren Y
    Beijing Da Xue Xue Bao Yi Xue Ban; 2017 Apr; 49(2):295-302. PubMed ID: 28416841
    [TBL] [Abstract][Full Text] [Related]  

  • 34. FoxO3a as a Positive Prognostic Marker and a Therapeutic Target in Tamoxifen-Resistant Breast Cancer.
    Pellegrino M; Rizza P; Donà A; Nigro A; Ricci E; Fiorillo M; Perrotta I; Lanzino M; Giordano C; Bonofiglio D; Bruno R; Sotgia F; Lisanti MP; Sisci D; Morelli C
    Cancers (Basel); 2019 Nov; 11(12):. PubMed ID: 31769419
    [No Abstract]   [Full Text] [Related]  

  • 35. Global characterization of signalling networks associated with tamoxifen resistance in breast cancer.
    Browne BC; Hochgräfe F; Wu J; Millar EK; Barraclough J; Stone A; McCloy RA; Lee CS; Roberts C; Ali NA; Boulghourjian A; Schmich F; Linding R; Farrow L; Gee JM; Nicholson RI; O'Toole SA; Sutherland RL; Musgrove EA; Butt AJ; Daly RJ
    FEBS J; 2013 Nov; 280(21):5237-57. PubMed ID: 23876235
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In silico discovery and validation of potent small-molecule inhibitors targeting the activation function 2 site of human oestrogen receptor α.
    Singh K; Munuganti RS; Leblanc E; Lin YL; Leung E; Lallous N; Butler M; Cherkasov A; Rennie PS
    Breast Cancer Res; 2015 Feb; 17(1):27. PubMed ID: 25848700
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of β-Catenin to Overcome Endocrine Resistance in Tamoxifen-Resistant Breast Cancer Cell Line.
    Won HS; Lee KM; Oh JE; Nam EM; Lee KE
    PLoS One; 2016; 11(5):e0155983. PubMed ID: 27196739
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Wnt signalling pathway is upregulated in an in vitro model of acquired tamoxifen resistant breast cancer.
    Loh YN; Hedditch EL; Baker LA; Jary E; Ward RL; Ford CE
    BMC Cancer; 2013 Apr; 13():174. PubMed ID: 23547709
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MEK activity controls IL-8 expression in tamoxifen-resistant MCF-7 breast cancer cells.
    Kim S; Jeon M; Lee JE; Nam SJ
    Oncol Rep; 2016 Apr; 35(4):2398-404. PubMed ID: 26780941
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Downregulation of 15-hydroxyprostaglandin dehydrogenase during acquired tamoxifen resistance and association with poor prognosis in ERα-positive breast cancer.
    Volpato M; Cummings M; Shaaban AM; Abderrahman B; Hull MA; Maximov PY; Broom BM; Hoppe R; Fan P; Brauch H; Jordan VC; Speirs V
    Explor Target Antitumor Ther; 2020; 1(5):355-371. PubMed ID: 33210098
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.